Arcellx

ACLX

Market cap $6.58B

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arcellx, Inc. (NasdaqGS: ACLX) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of Arcellx will receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. KSF is seeking to deter.

NEW YORK, Feb. 23, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Arcellx, Inc. (NASDAQ: ACLX ) related to its sale to Gilead Sciences, Inc. Under the terms of the proposed transaction, Arcellx shareholders are expected to receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones.

Shares of a biotech firm are jumping on a down day for stocks.

MILWAUKEE, Feb. 23, 2026 /PRNewswire/ -- Ademi LLP is investigating Arcellx (NASDAQ: ACLX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Gilead. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

MILWAUKEE, Feb. 23, 2026 /PRNewswire/ -- Ademi LLP is investigating Arcellx (NASDAQ: ACLX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Leonard Green & Partners. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't a mystery rally.

Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer treatments.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Arcellx, Inc. (NASDAQ: ACLX) to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. Halper Sadeh encourages Arcellx shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@ha.

Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.

Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.